1G. Vin?on,C. Baldit,P. Couzigou,F. Demotes-Mainard,L. Elouaer-Blanca,Dr. B. Bannwarth,B. Begaud. Pharmacokinetics of famotidine in patients with cirrhosis and ascites[J] 1992,European Journal of Clinical Pharmacology(5):559～562
2J. H. Lin,A. N. Chremos,K. C. Yeh,J. Antonello,G. A. Hessey. Effects of age and chronic renal failure on the urinary excretion kinetics of famotidine in man[J] 1988,European Journal of Clinical Pharmacology(1):41～46
3U. Klotz,P. Arvela,B. Rosenkranz. Famotidine, a new H2-receptor antagonist, does not affect hepatic elimination of diazepam or tubular secretion of procainamide[J] 1985,European Journal of Clinical Pharmacology(6):671～675
4Dr. J. Lacey Smith,Mohamed A. Gamal,A. N. Chremos,David Y. Graham. Famotidine, a new H2-receptor antagonist[J] 1985,Digestive Diseases and Sciences(4):308～312
7Yih V, Tejani A. Missed opportunities in the trail on proton pump inhibitor therapy in bleeding peptic ulcers [ J ]. Ann In- tern Med ,2009,151 ( 8 ) :588-589.
8Tajima A, Koizumi K, Sumuki K, et al. Proton pump inhibitors and recurrent bleeding in peptic ulcer disease[ J]. J Gastroen- terol Hepato1,2008,23 ( Suppl 2 ) :237.
9P6rez Flores R, Garcfa Molinero M J, Herrero Quir6s C, et al. The treatment of upper digestive hemorrhage of peptic origin : intravenous ranitidine versus intravenous omeprazole [ J ]. RevEsp Enferm Dig, 1994,86(3 ) :637-641.
10Mohamed SA, Karawi MA. Omeprazole versus histamine H2 receptor antagonists in the treatment of acute upper non- variceal bleeding [J ]. Hepatogastroenterology, 1996,43 ( 10 ) : 863 -865.
